Astra Zeneca and Merck partner on drug regimen
AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.
AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.
AZD6244 blocks the MEK pathway and is currently under investigation in skin, colorectal, and lung cancers. MK-2206 is an AKT pathway inhibitor that has shown promise in phase I testing in advanced solid tumors (ASCO 2009 abstract 3503).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
!["This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6934d676a539495d8b2109e4b3762700aa723bf3-1200x873.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population,\" according to the study authors.")
